Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | CCR3 | P51677 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7303580 | 0.99 | DRD2 (0.69) | DRD2CCR3MEN1CHRM2HTR1A | |
| SCHEMBL9053418 | 0.93 | CCR3 (0.65) | CCR3 | |
| Hydrochloric Acid SCHEMBL7305754 | 0.93 | MEN1 (0.69) | DRD2MEN1CHRM2HTR1AADRA2A | |
| SCHEMBL9050713 | 0.91 | CCR3 (0.66) | CCR3ADRA1A | |
| Hydrochloric Acid SCHEMBL9053162 | 0.90 | CCR3 (0.65) | CCR3ADRA1A | |
| SCHEMBL4499983 | 0.88 | CYP2J2 (0.65) | CCR3 | |
| SCHEMBL9051860 | 0.87 | DRD2 (0.67) | DRD2MEN1CHRM2HTR1AADRA2A | |
| SCHEMBL17023763 | 0.85 | CYP2J2 (0.70) | DRD2CCR3CHRM2HTR1AADRA2A | |
| SCHEMBL11364041 | 0.83 | DRD2 (0.61) | DRD2MEN1CHRM2HTR1AADRA2A | |
| SCHEMBL20652674 | 0.83 | DRD2 (1.00) | DRD2MEN1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | claimed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| CN-1303376-A | Compound with activity on muscarinic receptors | ACADIA PHARMACEUTICAL INC (US) | 2001-07-11 | — | — | CN | disclosed |
| WO-2001005763-A2 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CCR3 1121/4885MEN1 539/4885 |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | DRD2 185/4885CCR3 1286/4885MEN1 2626/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CCR3 1121/4885MEN1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.